Subsequently, TP53 mutations were identified [5], the CDKN2A gene was shown to be a consistent target of deletion [6], and mutations were found in both the TSC1 and FGFR3 genes in bladder cancer [7], [8], as well as many other genetic changes. This evidence concerns the gene FGFR3 and urinary bladder cancer.